Convincing new providers to offer medical abortion: What will it take?

Perspectives on Sexual and Reproductive Health

Volumn 35, Issue 1, 2003, Pages 44-47

  Coeytaux, Francine ^c   Moore, Kirsten ^a   Gelberg, Lillian ^b  

^a Repro Health Technologies Project   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

MIFEPRISTONE;

ABORTION; DRUG APPROVAL; DRUG INDICATION; FOOD AND DRUG ADMINISTRATION; HEALTH CARE DELIVERY; HUMAN; PREGNANCY; SHORT SURVEY;

ABORTIFACIENT AGENTS, STEROIDAL; ABORTION, INDUCED; FAMILY PLANNING SERVICES; FEMALE; HUMANS; INTERVIEWS; MIFEPRISTONE; PHYSICIAN'S PRACTICE PATTERNS; PHYSICIANS; PREGNANCY; PRIMARY HEALTH CARE; UNITED STATES;

EID: 0037256094     PISSN: 15386341     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1931-2393.2003.tb00086.x     Document Type: Short Survey

References (6)

1. Gellene D, RU-486 abortion pill hasn't caught on in U.S.; physicians have stayed away from medication and clinics are noncommittal, Los Angeles Times, May 31, 2001, p. 1.
2. Kaufman M, Abortion pill sales rising, firm says, Washington Post, Sept. 25, 2002, p. A3.
3. Kolata G, Abortion pill slow to win users among women and their doctors, New York Times, Sept. 25, 2002, p. A1.
4. Jones RK and Henshaw SK, Mifepristone in early medical abortion: experiences in France, Great Britain and Sweden, Perspectives on Sexual and Reproductive Health, 2002, 34(3):154-161.
5. Coeytaux F, Moore K and Gelberg L, What will it take to get new providers to begin dispensing Mifeprex: insights from an exploratory survey in California, unpublished manuscript, Los Angeles, Sept. 2002.
6. Winikoff B, Acceptability of medical abortion in early pregnancy, Family Planning Perspectives, 1995, 27(4):142-148 & 185.